Vera Therapeutics, Inc. — Form 8-K
Filed September 15, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Vera Therapeutics announced ORIGIN 3 final efficacy results for TRUTAKNA (atacicept-vymj) in IgA nephropathy: 428 patients showed placebo-adjusted eGFR stabilization of +5.6 mL/min/1.73m² at 52 weeks (p=0.0001) and 76% risk reduction in composite kidney disease progression (hazard ratio 0.24, p=0.0001). The company plans to submit a supplemental BLA in Q4 2026 for full FDA approval. Commercial momentum: 350+ patient start forms in first 10 weeks post-accelerated approval; cash position ~$499M plus $425M available via Oxford Facility.
Why this rating
Transformational clinical validation supporting full approval pathway significantly de-risks company; successful Phase 3 eGFR data directly enables market expansion in ~90K high-risk IgAN patients (est. $10B+ opportunity). Early commercial traction and solid balance sheet support execution, but regulatory approval still pending.
Tradability signal
NO TRADE
No trade: the filing reads positive but the market is selling it (-8.1% since it hit EDGAR) — when our read and the tape disagree this hard, we stand aside. (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
before filing · preread $39.11 ▲ 10.01% | at our read · unknown $35.55 | +10 min · unknown $34.10 ▼ 4.08% | +30 min · unknown $33.69 ▼ 5.23% | +1 hr · unknown $33.17 ▼ 6.69% | +4 hrs · unknown $33.16 ▼ 6.72% |
The stock had already moved -9.10% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from September 15, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.